https://www.selleckchem.com/pr....oducts/Masitinib-(AB
001), and total bilirubin (MD 2.08 mmol/L, 95%CI 1.36-2.80 mmol/L; P0.001) were observed in the severe COVID-19 group compared to non-severe COVID-19 group. Gastrointestinal symptoms and biomarkers should be assessed early to recognize severe COVID-19. Gastrointestinal symptoms and biomarkers should be assessed early to recognize severe COVID-19.Atrial fibrillation (AF) and nonalcoholic fatty liver disease (NAFLD) share common risk factors and appear to have an association. Independently, the incidence and prevalence of b
Me gusta
Comentario
Compartir
